Conference Presentation, Panel
Aligning Investment and Opportunity in Health | Global Conference 2026
- Large pharmaceutical firms are expected to evolve into pure-play entities after divesting consumer and animal health units, needing approximately $70 billion in risk-adjusted sales to sustain 4% annual growth over the next five years.
- Public company M&A activity is projected to have consumed $140 billion in the last six quarters and $105 billion since April 1, 2025, while early-stage public companies anticipate raising $250 million to $400 million, up from the previously achievable $100 million.
- Future IPOs are expected to resume featuring later-stage companies with less than a 10% probability of success compared to the 2019-2020 cycle, as generalist investors recognize the healthcare ecosystem is in the second inning relative to the tech sector's status from a decade prior.
- U.S. R&D spending is currently estimated at $300 billion annually, with expectations that China could eventually spend $400 billion per year on novel medicines if reaching 1% of GDP, matching current U.S. contribution levels.
- Clinical trial strategies anticipate rapid and lower-cost early-stage execution in China, whereas later-stage trials and commercialization will likely remain in the U.S. and Europe, with Chinese companies increasingly utilizing offshore subsidiaries to meet Western partnership preferences.
- AI is projected to have a near-term greater impact on healthcare delivery than drug discovery due to data limitations, with potential to improve trial success rates by 20% to 25% and reduce development time and costs by one to two years and 20% respectively.
- Investment incentives may shift away from non-orphan diseases of aging like Alzheimer's if Medicare price controls and the Inflation Reduction Act expand to all drugs and biologics within five years of launch, potentially crushing the innovation ecosystem.
- U.S. regulatory concerns regarding scientist attraction and the potential for expanded Medicare negotiations pose risks to the innovation pipeline, though drug inventors may gain negotiating leverage if billing directors prioritize prior authorizations for high-societal-value medicines.
- The commercial landscape is expected to favor chronic treatments approved at early diagnosis to generate immediate free cash flow, while oncology development is steering away from fourth or fifth-line approvals to preserve patent life before first-line approval.
- Innovation is anticipated to surge in inflammation, immunology, and organ failure solutions using pig organs with trials currently commencing for heart, lung, kidney, and liver failure, while patient and employer demand for specific coverage remains a critical factor in determining future medicine development.